Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Official title: A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-05-16
Completion Date
2027-05
Last Updated
2026-01-05
Healthy Volunteers
No
Conditions
Interventions
ZG005 for Injection
intravenous infusion
Gecacitinib Hydrochloride Tablets
Oral
Locations (1)
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China